Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and in situ reprogramming of cells.
The partnership is focused on developing candidate CAR-T therapies with promising clinical application prospects. It will leverage Nona Bio’s proprietary all-human heavy chain antibody platform, HCAb Harbour Mice, along with its newly launched site-directed coupling technology. This will be combined with Alaya.bio’s innovative polymer in situ delivery platform. In the initial phase, Nona Bio will provide antibodies with multiple targets as per Alaya.bio’s R&D plan. The second phase will see Alaya.bio select one or more antigen-binding molecules and use Nona Bio’s site-directed coupling technology to bind them with polymer nanoparticles. This approach is expected to expedite the clinical application of Alaya.bio’s CAR-T candidate products.- Flcube.com
